Icon

GLYXAMBI (nda206073)- (10MG;5MG,25MG;5MG)

EMPAGLIFLOZIN; LINAGLIPTIN BOEHRINGER INGELHEIM
10MG;5MG,25MG;5MG
Yes No
2034-Oct-03 2019-Aug-01
None None
None No
GLYXAMBI is a combination of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
0 9 0
Total Other Developers 10
Drugs with Suitability No
10MG;5MG ** ** Up - -
25MG;5MG ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.